Eli Lilly and Biogen Release Q4 Earnings Revealing a Pitfall in Their Alzheimer’s Disease Research

Equity Research Analyst, Laura Chico, appeared on TDAN to discuss the results of Eli Lilly and Biogen’s Q4 earnings report. She discusses how the two companies compare as they research amyloid antibodies’ effect on alzheimer’s disease.

For more comments from Laura Chico, view the full appearance.